Clinical trial

Efficacy and Safety Study With MYL-1401H and Neulasta

NCT02467868

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2015-03-01

PhasePHASE3

Study timeline

Study start (unknown)2015-03-01Date precision: month

Registry last updated2022-02-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Neoplasmsunresolved

Chemotherapy-Induced Febrile Neutropeniaunresolved

Interventions

MYL-1401HBIOLOGICAL

NeulastaBIOLOGICAL

Sponsors & collaborators

Mylan Inc.lead sponsor

Mylan GmbHcollaborator

Mapped research locations

BudapestHungary3 PlovdivBulgaria3 SofiaBulgaria2 KrakowPoland1 KyivUkraine1 BydgoszczPoland1 KharkivUkraine1 DebrecenHungary1 BonnGermany1 LvivUkraine1 VarnaBulgaria1 OdesaUkraine1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02467868 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.